BACKGROUND: Previous studies have demonstrated that @entity1 with @entity1569 have higher rates of comorbidities compared to the general population. Despite the clinical and economic burden of @entity5144 , there have been few large-scale observational studies focused on this condition. OBJECTIVE: To assess rates of cardiovascular, autoimmune, @entity166 and other conditions in @entity1 with @entity1569 or @entity5144 ( @entity5144 ). METHODS: The data for this retrospective study were obtained from the Clinical Practice Research Datalink (CRPD). Cohorts of @entity1 with @entity1569 (n  =  27  672; mild, n  =  22  174, severe, n  =  5498) and @entity5144 (n  =  1952) were generated based on the diagnosis made by general practitioner or specialist recorded in CPRD between 2006 and 2010. Frequencies of comorbidities at baseline and incidence rate ratios (IRR) of medical conditions occurring during follow-up were calculated and compared between groups. Cox proportional hazard models were employed to compare hazard ratios (HR) of comorbidities across the same subpopulations previously described. RESULTS: Significant differences in the unadjusted risk of @entity65 , hyperlipidaemia, @entity6 , @entity1489 and @entity792 were observed between @entity1 with differing severity of @entity1569 or between @entity5144 and @entity1569 @entity1 . The adjusted HR analyses confirmed @entity1 with severe @entity1569 had significantly higher rates of several conditions including @entity6 (1.23; 95% CI: 1.01-1.51) and @entity309 (2.88; 95% CI: 2.25-3.67) compared to @entity1 with mild @entity1569 . @entity1 with @entity5144 had significantly higher adjusted rates of @entity101 (1.30; 95% CI: 1.01-1.68), @entity309 (6.93; 95% CI: 5.45-8.80) and @entity1691 (6.98; 95% CI: 2.37-20.58) compared to those with severe @entity1569 . CONCLUSION: @entity1 with mild @entity1569 are less affected by comorbid conditions than those with severe @entity1569 , and @entity1 with @entity1569 are less affected by comorbidities than those with @entity5144 . Given the differences observed across severities of @entity1569 and between @entity1569 and @entity5144 , each @entity1 subgroup should be taken into consideration in clinical practice and future research.

Prevalence and incidence rates of cardiovascular, autoimmune, and other diseases in @entity1 with XXXX : a retrospective study using Clinical Practice Research Datalink.

@entity1 :: ('9606', 'Species') :: ['Patients', 'patients', 'patient'] @entity1569 :: ('MESH:D011565', 'Disease') :: ['psoriasis'] @entity6 :: ('MESH:D003920', 'Disease') :: ['diabetes'] @entity309 :: ('MESH:D001172', 'Disease') :: ['rheumatoid arthritis'] @entity101 :: ('MESH:D006973', 'Disease') :: ['hypertension'] @entity1489 :: ('MESH:D012878', 'Disease') :: ['skin cancer'] @entity5144 :: ('MESH:D015535', 'Disease') :: ['PSA', 'psoriatic disease', 'psoriatic arthritis'] @entity1691 :: ('MESH:D013167', 'Disease') :: ['ankylosing spondylitis'] @entity792 :: ('MESH:D001327', 'Disease') :: ['autoimmune diseases'] @entity166 :: ('MESH:D003141', 'Disease') :: ['infectious'] @entity65 :: ('MESH:D002318', 'Disease') :: ['cardiovascular disease']
@entity5144 :: (MESH:D015535,Disease) :: ['psoriatic or psoriatic arthritis']
